# Veracyte Inc. (VCYT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $42.53, market value $3.4 billion.

## Valuation
- **P/E (trailing): 30.4×** (5-yr avg 89.5×, 3-yr avg 89.5×). Veracyte Inc. trades at 30.4× trailing earnings, well below its own five-year average of 89.5×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 21.8×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.13**. A PEG of 0.13 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 6.1×**. Each dollar of revenue is priced at 6.1×.
- **Price / book: 2.5×**. The shares trade at 2.5× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 24.1×**. Enterprise value is 24.1× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 4.9%** (5-yr avg 1.2%). Free cash flow equals 4.9% of the market value, above its five-year average of 1.2%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 3.3%**. The inverse of the P/E: 3.3% of the price is earned each year.

## Profitability
- **Gross margin: 71.7%**. Veracyte Inc. keeps 71.7% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 18.8%**. 18.8% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 12.8%**. 12.8% of each dollar of sales reaches the bottom line.
- **Return on equity: 5.1%**. 5.1% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 8.8%**. Return on all capital, debt included, is 8.8%.
- **Return on assets: 8.1%**. Each dollar of assets produces 8.1% of profit.

## Growth
- **Revenue growth (1 yr): 16.0%** (3-yr 20.4%/yr, 5-yr 34.5%/yr). Revenue grew 16.0% over the last year, against 34.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 164.5%**. Earnings per share rose 164.5%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Veracyte Inc. holds more cash than debt.
- **Current ratio: 8.15** (quick 8.15). Current assets cover the next year's liabilities 8.15 times.
- **Altman Z-score: 23.44**. A Z-score of 23.44 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 8/9**. 8 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Veracyte Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 34.9%** (YTD 1.0%, 3-mo -12.7%). The shares are up 34.9% over twelve months including dividends.
- **From 52-week high: -30.2%** (44.4% above the low). Trading 30% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 41**. An RSI of 41 is neutral.
- **Beta (1 yr): 1.50** (volatility 63%). Beta of 1.50 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=VCYT · Page: https://foliofundamentals.com/stocks/vcyt

Not investment advice.